Sabina Russo

1.3k total citations
25 papers, 648 citations indexed

About

Sabina Russo is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Sabina Russo has authored 25 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Hematology and 8 papers in Genetics. Recurrent topics in Sabina Russo's work include Eosinophilic Disorders and Syndromes (6 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Sabina Russo is often cited by papers focused on Eosinophilic Disorders and Syndromes (6 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Sabina Russo collaborates with scholars based in Italy and Spain. Sabina Russo's co-authors include Alessandro Allegra, Caterina Musolino, Andrea Alonci, Demetrio Gerace, Vanessa Innao, Giuseppa Penna, Sebastiano Gangemi, Antonino Cannavò, Mariateresa Cristani and Giovanna Spatari and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and International Journal of Molecular Sciences.

In The Last Decade

Sabina Russo

22 papers receiving 636 citations

Peers

Sabina Russo
Sabina Russo
Citations per year, relative to Sabina Russo Sabina Russo (= 1×) peers Demetrio Gerace

Countries citing papers authored by Sabina Russo

Since Specialization
Citations

This map shows the geographic impact of Sabina Russo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabina Russo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabina Russo more than expected).

Fields of papers citing papers by Sabina Russo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabina Russo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabina Russo. The network helps show where Sabina Russo may publish in the future.

Co-authorship network of co-authors of Sabina Russo

This figure shows the co-authorship network connecting the top 25 collaborators of Sabina Russo. A scholar is included among the top collaborators of Sabina Russo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabina Russo. Sabina Russo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stagno, Fabio, Sabina Russo, Giuseppe Murdaca, et al.. (2025). Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia. International Journal of Molecular Sciences. 26(6). 2535–2535. 3 indexed citations
2.
Stagno, Fabio, Stefania Stella, Salvatore Leotta, et al.. (2025). No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level. International Journal of Molecular Sciences. 26(5). 1840–1840.
3.
Santoro, Marco, Sabina Russo, Iolanda Donatella Vincelli, et al.. (2023). Real-Life Data of Bosutinib Treatment for Chronic Myeloid Leukemia: The Multi-Center Experience of the Gruppo Di Miglioramento Sicilia-Calabria. Blood. 142(Supplement 1). 6375–6375.
4.
Stella, Stefania, Elena Tirrò, Michele Massimino, et al.. (2019). Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. In Vivo. 33(5). 1593–1598. 6 indexed citations
5.
Allegra, Alessandro, Giuseppa Penna, Vanessa Innao, et al.. (2015). Vaccination of multiple myeloma: Current strategies and future prospects. Critical Reviews in Oncology/Hematology. 96(2). 339–354. 23 indexed citations
6.
Musolino, Caterina, Alessandro Allegra, Carmen Mannucci, et al.. (2015). Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity. SHILAP Revista de lepidopterología. 32(2). 168–171. 9 indexed citations
7.
Campo, Salvatore, Alessandro Allegra, Angela D’Ascola, et al.. (2014). MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. British Journal of Haematology. 165(6). 801–813. 19 indexed citations
8.
Allegra, Alessandro, Andrea Alonci, Demetrio Gerace, et al.. (2013). New orally active proteasome inhibitors in multiple myeloma. Leukemia Research. 38(1). 1–9. 61 indexed citations
9.
Gangemi, Sebastiano, Alessandro Allegra, Mirella Profita, et al.. (2013). Decreased Plasma Levels of IL-33 Could Contribute to the Altered Function of Th2 Lymphocytes in Patients with Polycythemia Vera and Essential Thrombocythemia. Cancer Investigation. 31(3). 212–213. 11 indexed citations
10.
Allegra, Alessandro, Giuseppa Penna, Andrea Alonci, et al.. (2013). Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. European Journal Of Haematology. 90(6). 441–468. 44 indexed citations
11.
Musolino, Caterina, Alessandro Allegra, Antonella Saija, et al.. (2012). Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia. Clinical Biochemistry. 45(16-17). 1439–1443. 37 indexed citations
13.
Gangemi, Sebastiano, Alessandro Allegra, Andrea Alonci, et al.. (2012). Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflammation Research. 61(10). 1063–1067. 56 indexed citations
14.
Musolino, Caterina, Alessandro Allegra, Andrea Alonci, et al.. (2011). Carbonyl group serum levels are associated with CD38 expression in patients with B chronic lymphocytic leukemia. Clinical Biochemistry. 44(17-18). 1487–1490. 15 indexed citations
15.
Allegra, Alessandro, Giuseppa Penna, Andrea Alonci, et al.. (2011). Nanoparticles in Oncology: The New Theragnostic Molecules. Anti-Cancer Agents in Medicinal Chemistry. 11(7). 669–686. 36 indexed citations
16.
Penna, Giuseppa, Alessandro Allegra, Andrea Alonci, et al.. (2011). MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin’s variant of Richter’s syndrome. Oncology Letters. 2(2). 379–381. 1 indexed citations
17.
Allegra, Alessandro, Emanuela Sant’Antonio, Giuseppa Penna, et al.. (2010). Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors. European Journal Of Haematology. 86(2). 93–110. 43 indexed citations
18.
Allegra, Alessandro, Andrea Alonci, Giacomo Bellomo, et al.. (2010). Serum levels of Interleukin‐16 in a multiple myeloma patient with cutaneous involvement. International Journal of Dermatology. 49(4). 435–437. 4 indexed citations
19.
Musolino, Caterina, Emanuela Sant’Antonio, Giuseppa Penna, et al.. (2010). Epigenetic therapy in myelodysplastic syndromes. European Journal Of Haematology. 84(6). 463–473. 26 indexed citations
20.
Allegra, Alessandro, Andrea Alonci, Sabina Russo, et al.. (2010). Cardiac involvement in patients with hematologic malignancies.. PubMed. 58(7). 859–74. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026